ECSP17075386A - Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina - Google Patents

Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina

Info

Publication number
ECSP17075386A
ECSP17075386A ECIEPI201775386A ECPI201775386A ECSP17075386A EC SP17075386 A ECSP17075386 A EC SP17075386A EC IEPI201775386 A ECIEPI201775386 A EC IEPI201775386A EC PI201775386 A ECPI201775386 A EC PI201775386A EC SP17075386 A ECSP17075386 A EC SP17075386A
Authority
EC
Ecuador
Prior art keywords
ketamine
csa
salt
processes
preparation
Prior art date
Application number
ECIEPI201775386A
Other languages
English (en)
Inventor
Cheng Yi Chen
Tobias Wedel
Adrian Maurer
Tobias Strittmatter
Oliver Floegel
Karl Reuter
Michael Justus
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56068863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17075386(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP17075386A publication Critical patent/ECSP17075386A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/23—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención está dirigida a procesos para la preparación de esketamina. La presente invención está dirigida, además, a procesos para la resolución de S-ketamina a partir de una mezcla racémica o enantioméricamente enriquecida de ketamina. La presente invención está dirigida, además, a una sal de (S)-CSA de S-ketamina, más particularmente, una forma monohidrato de la sal de (S)-CSA de S-ketamina; y a una sal de (R)-CSA de R-ketamina.
ECIEPI201775386A 2015-05-13 2017-11-13 Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina ECSP17075386A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562160659P 2015-05-13 2015-05-13

Publications (1)

Publication Number Publication Date
ECSP17075386A true ECSP17075386A (es) 2018-02-28

Family

ID=56068863

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201775386A ECSP17075386A (es) 2015-05-13 2017-11-13 Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina

Country Status (24)

Country Link
US (3) US20160332962A1 (es)
EP (1) EP3294704B1 (es)
JP (1) JP6882990B2 (es)
KR (1) KR102610047B1 (es)
CN (1) CN107750245B (es)
AU (1) AU2016260911B2 (es)
BR (1) BR112017024243B1 (es)
CA (1) CA2985696A1 (es)
CL (3) CL2017002854A1 (es)
CO (1) CO2017011553A2 (es)
CR (1) CR20170517A (es)
EA (1) EA201792503A1 (es)
EC (1) ECSP17075386A (es)
ES (1) ES2767708T3 (es)
GT (1) GT201700245A (es)
IL (1) IL255433B2 (es)
MX (1) MX377053B (es)
MY (1) MY181938A (es)
PE (1) PE20180527A1 (es)
PH (2) PH12017502024B1 (es)
SA (1) SA517390322B1 (es)
UA (1) UA121049C2 (es)
WO (1) WO2016180984A1 (es)
ZA (1) ZA201708417B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
KR20170040800A (ko) 2014-08-13 2017-04-13 얀센 파마슈티카 엔.브이. 우울증 치료 방법
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
KR20240011237A (ko) 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 우울증 치료를 위한 에스케타민
ES2907692T3 (es) * 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
CN110218157B (zh) * 2018-03-01 2022-08-23 江苏恒瑞医药股份有限公司 一种r-氯胺酮及其可药用盐的制备方法
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
BR112020023882A2 (pt) 2018-06-27 2021-02-09 Clexio Biosciences Ltd. método para tratar transtorno depressivo maior
CN108659004B (zh) * 2018-07-12 2020-11-10 福安药业集团重庆博圣制药有限公司 奥拉西坦异构体的制备方法
CN112702995A (zh) 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾氯胺酮的治疗方案
JP2022524008A (ja) 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン
EP3956300A1 (en) * 2019-04-16 2022-02-23 Janssen Pharmaceutica NV Synthetic methods of preparing esketamine
CN112375005A (zh) * 2019-08-16 2021-02-19 国药集团工业有限公司 一种氯胺酮、其衍生物或其盐的消旋化方法
EP4084786A1 (en) 2019-12-30 2022-11-09 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
WO2022208144A1 (en) * 2021-03-31 2022-10-06 Supriya Lifescience Ltd A crystalline form of 2-(2-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride and method thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) * 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS5857420B2 (ja) * 1975-02-12 1983-12-20 ワコウジユンヤクコウギヨウ カブシキガイシヤ Ｄｌ− フエニルグリシンノ コウガクブンカツホウホウ
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
JPS6314771A (ja) * 1986-07-08 1988-01-21 Sankyo Co Ltd 光学活性イミダゾ−ル誘導体およびその製法
JPS63192753A (ja) * 1987-02-05 1988-08-10 Otsuka Pharmaceut Co Ltd テトラヒドロキノリン誘導体の光学分割法
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
WO1996011894A1 (en) 1994-10-17 1996-04-25 Akzo Nobel N.V. Process for separating enantiomers from a racemic mixture
PE8798A1 (es) 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
DE19619665C2 (de) * 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
TW430660B (en) * 1996-05-30 2001-04-21 Mochida Pharm Co Ltd Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them
RU2224523C2 (ru) 1998-07-24 2004-02-27 Сео Хонг Ю Водный раствор, содержащий желчную кислоту, и способ его получения
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
BRPI0002693B8 (pt) * 2000-06-19 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
CA2529857A1 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
AU2007229866A1 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
WO2007122130A1 (en) * 2006-04-21 2007-11-01 Zach System S.P.A. Process for preparing dorzolamide
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
WO2009131794A1 (en) * 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
EP2992877A1 (en) 2010-06-15 2016-03-09 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
US9012486B2 (en) * 2011-11-14 2015-04-21 Alex Chervinsky Topical composition for pain relief
RU2622082C2 (ru) 2011-11-14 2017-06-09 Нестек С.А. Анализы и способы выбора режима лечения пациента с депрессией
WO2013138322A1 (en) 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
KR20150096370A (ko) 2012-08-23 2015-08-24 스튜어트 엘. 웨그 항불안제 조성물, 제형 및 사용방법
HK1212673A1 (zh) * 2012-10-08 2016-06-17 奥克兰服务有限公司 氯胺酮衍生物
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
DK2968221T3 (da) 2013-03-15 2019-08-05 Janssen Pharmaceutica Nv Farmaceutisk sammensætning af s-ketaminhydrochlorid
DK2983787T3 (da) 2013-04-12 2020-01-06 Icahn School Med Mount Sinai Fremgangsmåde til behandling af posttraumatisk stresssygdom
HUE056378T2 (hu) * 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression

Also Published As

Publication number Publication date
UA121049C2 (uk) 2020-03-25
JP6882990B2 (ja) 2021-06-02
WO2016180984A1 (en) 2016-11-17
IL255433B1 (en) 2023-03-01
BR112017024243A2 (pt) 2018-07-17
IL255433A (en) 2018-02-28
GT201700245A (es) 2019-08-07
CL2017002854A1 (es) 2018-04-20
EA201792503A1 (ru) 2018-02-28
KR20180008568A (ko) 2018-01-24
PE20180527A1 (es) 2018-03-19
CN107750245B (zh) 2021-06-22
CR20170517A (es) 2017-12-05
JP2018516891A (ja) 2018-06-28
EP3294704A1 (en) 2018-03-21
US20210024461A1 (en) 2021-01-28
ES2767708T3 (es) 2020-06-18
ZA201708417B (en) 2018-11-28
SA517390322B1 (ar) 2023-07-16
BR112017024243B1 (pt) 2021-12-07
US10815196B2 (en) 2020-10-27
CL2019001066A1 (es) 2019-06-21
PH12017502024B1 (en) 2023-04-05
HK1251546A1 (zh) 2019-02-01
CN107750245A (zh) 2018-03-02
PH12021552213A1 (en) 2022-07-18
AU2016260911B2 (en) 2020-02-27
US20180282266A1 (en) 2018-10-04
IL255433B2 (en) 2023-07-01
CA2985696A1 (en) 2016-11-17
CL2020001852A1 (es) 2020-10-23
EP3294704B1 (en) 2019-10-30
MX377053B (es) 2025-03-07
US20160332962A1 (en) 2016-11-17
MY181938A (en) 2021-01-14
PH12017502024A1 (en) 2018-04-02
MX2017014473A (es) 2018-03-21
CO2017011553A2 (es) 2018-04-19
KR102610047B1 (ko) 2023-12-05
AU2016260911A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
ECSP17075386A (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
MX380263B (es) Procesos para producir brivaracetam.
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
MX387796B (es) Compuestos de aminocarbonilcarbamato.
CO2017001389A2 (es) Compuestos de azetidiniloxifenilpirrolidina
BR112017019850A2 (pt) ?processo melhorado para a preparação de apremilast?
MX384794B (es) Proceso para la preparacion de 5-fluoro-1h-pirazoles a partir de hexafluoropropeno.
BR112015024859A2 (pt) processo e intermediários para a preparação de pregabalina
EA201791645A1 (ru) Новые соли и полиморфы scy-078
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
BR112016023767A2 (pt) forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações
BR112018069255A2 (pt) processos para a preparação de ácidos heteroaril carboxílicos
MX2016015623A (es) Proceso para la preparacion de derivados dihidroisoxazol.
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
BR112019002828A2 (pt) método de preparação de derivados de estireno substituído
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.
MX2016016398A (es) Preparacion de piperidin-4-carbotioamida.
BR112015028751A2 (pt) processo para a preparação de derivados de 3,5-bis (fluoralquil)pirazol a partir de alfa,alfa-dihaloaminas
MX2017011388A (es) Proceso para la preparacion de derivados de fenilisoxazolina sustituida.
UA112041C2 (uk) N-(4-ТРИФЛЮОРОМЕТИЛФЕНІЛ)-4-ГІДРОКСИ-2,2-ДІОКСО-1H-2λ6,1-БЕНЗОТІАЗИН-3-КАРБОКСАМІД, ЯКИЙ ВИЯВЛЯЄ АНАЛЬГЕТИЧНУ АКТИВНІСТЬ
UA114161C2 (xx) Сіль 3-карбокси-4-(r)-фенілпіролідин-2-ону та її застосування